Zilong Wang

Dr. Zilong Wang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in BMC Urology
Verified
Journal Article
Open access
PDF file
JCJunhao Chu
Junhao Chu
ZZZhihui Zhang
Zhihui Zhang
HYHuisheng Yuan
Huisheng Yuan
JKJiajun Kan
Jiajun Kan
ZWZilong Wang
Zilong Wang
MWMuwen Wang
Muwen Wang
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with malignant potential, affecting various anatomical regions, predominantly the head and neck. Urogenital involvement is relatively uncommon. In particular, penile neurofibromatosis is exceedingly rare, with fewer than 20 cases documented globally. In China, only four pediatric cases have been reported, with no known occurrences in adults. To date, no recurrent penile plexiform neurofibromas have been reported in adults. Here, we report a rare case of a recurrent giant penile plexiform neurofibroma, accompanied by multiple neurofibromas involving the prostate, bladder, and retroperitoneum, in an adult NF1 patient. A 37-year-old male patient initially presented to the Department of Urology, Shandong First Medical University Affiliated Provincial Hospital, on April 17, 1994 (at the age of 8), with a seven-year history of painless penile enlargement. He underwent resection of the penile mass, with histopathological analysis confirming a diagnosis of plexiform neurofibroma. Following surgery, the penile morphology normalized. However, at the age of 20, he experienced recurrent painless penile enlargement but did not pursue further medical evaluation. On October 7, 2023, the patient was readmitted due to right flank pain and hydronephrosis. Physical examination revealed marked penile enlargement with a palpable large mass and multiple café-au-lait macules across the body. Although the patient had no urinary complaints, he was unable to achieve normal erectile function. Laboratory findings indicated an elevated serum creatinine level of 124.20 µmol/L. Imaging modalities, including computed tomography urography (CTU), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT), identified a massive penile tumor with concomitant multiple tumors in the prostate, bladder, and retroperitoneum. Penile tumor biopsy confirmed the diagnosis of plexiform neurofibroma. Immunohistochemical analysis demonstrated S-100 (+), recombinant human SOX10 protein (SOX10) (+), and Ki-67+ (< 1%). Given the histopathological results and clinical findings, the patient was diagnosed with neurofibromatosis type 1. To alleviate right flank pain, percutaneous nephrostomy was performed, resulting in a reduction in serum creatinine to 90.80 µmol/L within three days post-procedure, with subsequent symptom relief. Owing to extensive tumor infiltration and financial limitations, the patient opted against radical surgery or systemic therapy. He was subsequently discharged and has since been monitored with biannual follow-ups, including regular nephrostomy tube replacement. As of the latest follow-up, his clinical status remains stable without evidence of significant disease progression. This case report describes a rare adult patient with neurofibromatosis type 1, presenting with recurrent giant penile plexiform neurofibroma accompanied by multiple neurofibromas involving the prostate, bladder, and retroperitoneum. To the best of our knowledge, this combination of manifestations represents the first reported case. The patient underwent only percutaneous nephrostomy to alleviate symptoms, without pursuing additional treatment. Follow-up evaluations indicated a stable clinical course, suggesting that certain NF1 patients may achieve long-term stability without aggressive therapeutic intervention. This case underscores the importance of comprehensive evaluation, prolonged surveillance, and multidisciplinary management for NF1 patients, particularly those with extensive and atypical disease manifestations. Treatment decisions should consider a balance between patient preferences and the natural progression of the disease. This report offers valuable insights into the management of similar cases.

6 February 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JCJunhao Chu
Junhao Chu
HYHuisheng Yuan
Huisheng Yuan
ZZZhihui Zhang
Zhihui Zhang
JKJiajun Kan
Jiajun Kan
SDShishuai Duan
Shishuai Duan
MWMuwen Wang
Muwen Wang
Background: Bladder inflammatory myofibroblastic tumor (IMT) is a rare intermediate malignancy. Muscle-invasive bladder IMT is associated with a high risk of recurrence and metastasis, and bladder-sparing treatments for this condition are still under exploration. This case aims to evaluate the therapeutic efficacy of 1470 nm diode laser transurethral en bloc resection (ERBT) followed by laparoscopic partial cystectomy in the treatment of muscle-invasive bladder IMT.Methods and results: A 23-year-old male patient presented with painless terminal gross hematuria and was treated at Shandong Provincial Hospital of Shandong First Medical University. Computed tomography urography (CTU) and magnetic resonance imaging (MRI) identified a large tumor on the anterior bladder wall with muscle layer invasion, measuring approximately 5.0 × 3.9 × 4.3 cm. The patient underwent 1470 nm laser ERBT, followed by laparoscopic partial cystectomy 35 days later. Pathological examination following 1470 nm laser resection confirmed the diagnosis of an IMT with malignant potential, showing anaplastic lymphoma kinase (ALK) positivity, a Ki-67 index of 20% in hotspot regions, and ALK gene rearrangement detected by fluorescence in situ hybridization (FISH). Pathology after the secondary laparoscopic partial cystectomy showed tumor invasion into the superficial muscle layer, with negative margins at the resection site. MRI and cystoscopy showed no recurrence during 1 year follow-up.Conclusion: This case presents a patient with a huge muscle-invasive bladder IMT who received bladder-sparing therapy through 1470 nm diode laser ERBT followed by laparoscopic partial cystectomy. During subsequent follow-ups, the patient showed good recovery with no signs of recurrence, providing a promising treatment concept for bladder-sparing therapy in muscle-invasive bladder IMT.